REFERENCES
- Perry CM, Noble S. Didanosine: an updated review of its use in HIV infection. Drug. 1999;58:1099–1135.
- Moreno S, Hernández E, Dronda F. Didanosine enteric-coated capsule: current role in patients with HIV-1 infec-tion. Drug. 2007;67:1441–1462.
- Kovari H, Ledergerber B, Peter U, et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis. 2009;49: 626–635.
- Gazzard BG, on behalf of the BHIVA Treatment Guidelines. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563–608.
- Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009). Panel de expertos Gesida y Plan Nacional del sida. Enferm Infecc Microbiol Clin. 2009;27:222–235.
- Palacios R, Aguilar I, Hidalgo A, Santos J. Didanosine, lamivudine-emtricitabine and efavirenz as initial ther-apy in naive patients. Exp Rev Anti Infect Ther. 2006;4: 965–971.
- Fisher M, Moyle GJ, Shahmanesh M, et al. Randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtric-itabine in efavirenz-treated HIV-1—infected individuals. J Acquir Immune Defic Syndr 2009;51:562–568.
- DeJesus E, Pozniak A, Gallant J, et al. Improvement in fasting lipids but minimal recovery of limb fat were seen 96 weeks after switching from lamivudine/zidovudine plus efavirenz to fixed-dose efavirenz/emtricitabine/tenofovir DF in HIV-infected patients. Presented at: 49th Inter-science Conference on Antimicrobial Agents and Chemo-therapy (ICAAC); September 12–15, 2009; San Francisco, CA USA. Poster Number H–1572.